Connect with us


Patient data firm raises £5m for expansion



London-based uMotif, a patient data capture firm, has raised £5 million in a series A investment round led by existing investor AlbionVC.

The funding, which also saw participation from Oslo-based DNV-GL and existing angel investors, will be used to grow the company’s team, hiring talent across its engineering, services, and commercial departments. uMotif says this will enable the company to support a higher demand for decentralised research following the Covid-19 pandemic.

uMotif currently supports oncology, cardiology, and CNS trials. With its recent funding, the company intends to expand into new study types and more high-demand territories.

Bruce Hellman, CEO and co-founder of uMotif, says: “We would like to branch into infectious disease, pain management, and vaccine studies.

“We’re excited to help our customers implement patient-centred research designs by using the uMotif platform to capture high-quality data.

“This new funding will rapidly accelerate our development and will ultimately help our customers to get new therapies to patients faster.”

Life sciences companies are increasingly embracing decentralised and virtual study designs – where patient consent and data is captured using their own devices from wherever they are located.

This is in contrast to the centralised studies in which patients are required to visit a site, such as a hospital, to submit their data. The trend towards a decentralised model has been catalysed by COVID-19.

Dr. Andrew Elder, deputy managing partner at AlbionVC says: “Now more than ever, having access to reliable patient data during clinical trials is crucial.

“uMotif’s platform is built with patients in mind; designed to help academics, researchers and healthcare professionals to capture the best quality data in a way that suits the participants.

“It’s a win-win for all stakeholders and the platform has the potential and momentum to revolutionise the speed and efficiency with which therapies can reach and help millions of patients.”

uMotif says its innovative decentralised and patient-centric approaches increase how engaged patients are, thus improving the chances of the study’s success, reduce burden on participants, and help reach new patient populations to increase study diversity.

A decentralised model also has the potential to save time. Hellman says: “Each clinical trial has different timelines but one example of a study we managed finished six months earlier than planned due to hitting the patient data volume target early.”

uMotif’s cloud-based platform is used by global pharmaceutical and biotech companies to capture eConsentand clinical research data, including ePRO (Electronic patient-reported outcome), symptom, and wearable device data.

uMotif says its strengths lie in the way it works with and keeps thousands of research participants engaged.

With studies taking place in 26 countries from clinical to real-world settings, and across more than 25 therapeutic areas – from dermatology and rare disease to oncology and cardiology, uMotif’s focus is to foster an engaging patient experience to capture larger volumes of higher quality data.

New funding, Hellman says, will further enhance uMotif’s configurable software platform to support existing studies and support new study designs.

Hellman says: “We intend to develop more fully virtual studies, using a BYOD (Bring Your Own Device) approach. This is where patients use their own smart devices to collect and submit their data from wherever they are located rather than having the burden of travelling to a specific site, such as a hospital.”

With a customer base spanning Europe and the US, the investment will be used to drive commercial growth and enable further geographical expansion, including further expansion into the US market.

Hellman says: “We currently have customers based in the US and run clinical trials located there but we do that from the team based in London. We are looking to hire team members in the US to further expand our market share there.

Kaare Helle, venture director at DNV GL adds: “Healthcare is dependent on digital transformation if it is to move towards being a more sustainable sector. uMotif has developed a digital platform that can support new models of clinical trials while also ensuring that the patient voice is heard.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *